Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
Feature|Articles|September 1, 2026
Exploring the Real Reasons Why RBQM Implementation Fails
Author(s)Fred Blais
RBQM implementations fail not because the software is wrong — but because the human environment surrounding it was never engineered.
Advertisement
Advertisement
There is a myth in our industry that when an RBQM implementation fails to deliver the cause must be technical. It was the wrong platform. The dashboards lack clarity. The vendor overpromised and under-delivered. This myth suggests that if a new system is chosen, the failure will be resolved.
Related to this article
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Dr. Elena Christofides on why cortisol dysregulation may be the hidden reason GLP-1s fail — and what to do when patients don't respond.
Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.
AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
Advertisement
Advertisement